Drug development has become increasingly competitive and leaves little room for error or delay. Selecting and optimizing the right candidate is critical, allowing you to de-risk your development process and maximize your chances of a successful First-in-Human campaign. In our latest Q&A with our expert Dr. Rebecca Michael, learn about how in silico and in vitro design and optimization tools can help you not only assess risks but also mitigate them, and shape customized strategies to accelerate your path to the clinic.
Author: Rebecca Michael, Ph.D., Head of Cell and Molecular Biology, in Lonza Early Development Services